Scholarlink

Background <p>Curcumin and <i>Curcuma longa</i> extract have been proposed as adjunct therapies for autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) due to their anti-inflammatory and immunomodulatory properties. The purpose of this study was to determine the effects of curcumin and <i>Curcuma longa</i> extract on inflammatory biomarkers in patients with RA and SLE.</p> Methods <p>PubMed, EMBASE, and Cochrane CENTRAL databases were searched to May 14, 2025. Randomized controlled trials (RCTs) comparing curcumin or <i>Curcuma longa</i> extract with placebo or standard therapy in patients with RA or SLE were included. The primary outcomes were changes in disease activity score (DAS-28), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level analyzed using standardized mean differences (SMDs) with a random-effects model. Heterogeneity was assessed using the I<sup>2</sup> statistic, and sensitivity analyses were conducted using a leave-one-out approach.</p> Results <p>Seven RCTs involving 314 patients were included. The meta-analysis revealed no significant effect of curcumin or <i>Curcuma longa</i> extract on DAS-28 (pooled SMD = − 2.34, 95% confidence level [CI]: − 5.13 to 0.44; I<sup>2</sup> = 96.0%), ESR (pooled SMD = − 1.49, 95% CI − 3.71 to 0.72; I<sup>2</sup> = 91.7%), or CRP (pooled SMD = − 1.65, 95% CI − 3.88 to 0.58; I<sup>2</sup> = 91.6%). Substantial heterogeneity was observed across all outcomes.</p> Conclusions <p>This meta-analysis suggests that curcumin and <i>Curcuma longa</i> extract have limited and inconsistent effects on inflammatory biomarkers in patients with RA and SLE. Larger, well-designed RCTs are needed to clarify their clinical utility as adjunct therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of curcumin and Curcuma longa extract on inflammatory biomarkers in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE): a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Ang-Jun Liu,
  • Po-Chang Wu,
  • Yu-Pei Chen,
  • Hsueh-Ting Chu,
  • Hen-Hong Chang

摘要

Background

Curcumin and Curcuma longa extract have been proposed as adjunct therapies for autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) due to their anti-inflammatory and immunomodulatory properties. The purpose of this study was to determine the effects of curcumin and Curcuma longa extract on inflammatory biomarkers in patients with RA and SLE.

Methods

PubMed, EMBASE, and Cochrane CENTRAL databases were searched to May 14, 2025. Randomized controlled trials (RCTs) comparing curcumin or Curcuma longa extract with placebo or standard therapy in patients with RA or SLE were included. The primary outcomes were changes in disease activity score (DAS-28), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level analyzed using standardized mean differences (SMDs) with a random-effects model. Heterogeneity was assessed using the I2 statistic, and sensitivity analyses were conducted using a leave-one-out approach.

Results

Seven RCTs involving 314 patients were included. The meta-analysis revealed no significant effect of curcumin or Curcuma longa extract on DAS-28 (pooled SMD = − 2.34, 95% confidence level [CI]: − 5.13 to 0.44; I2 = 96.0%), ESR (pooled SMD = − 1.49, 95% CI − 3.71 to 0.72; I2 = 91.7%), or CRP (pooled SMD = − 1.65, 95% CI − 3.88 to 0.58; I2 = 91.6%). Substantial heterogeneity was observed across all outcomes.

Conclusions

This meta-analysis suggests that curcumin and Curcuma longa extract have limited and inconsistent effects on inflammatory biomarkers in patients with RA and SLE. Larger, well-designed RCTs are needed to clarify their clinical utility as adjunct therapies.